Dara Biosciences Inc (DARA) financial statements (2020 and earlier)

Company profile

Business Address 8601 SIX FORKS ROAD SUITE 160
RALEIGH, NC 27615
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2015
TTM
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1237
Cash and cash equivalents 1236
Short-term investments   0
Receivables 100
Inventory, net of allowances, customer advances and progress billings 000
Inventory 000
Prepaid expense and other current assets0
Other undisclosed current assets 00 
Total current assets: 1447
Noncurrent Assets
Property, plant and equipment 000
Intangible assets, net (including goodwill) 445
Goodwill 111
Intangible assets, net (excluding goodwill) 334
Restricted cash and investments 000
Prepaid expense and other noncurrent assets0
Total noncurrent assets: 445
TOTAL ASSETS: 18812
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 222
Accounts payable 011
Accrued liabilities 110
Employee-related liabilities 100
Debt 000
Other undisclosed current liabilities 100
Total current liabilities: 422
Noncurrent Liabilities
Long-term debt and lease obligation 000
Capital lease obligations 000
Liabilities, other than long-term debt 000
Deferred revenue and credits 000
Other undisclosed noncurrent liabilities  11
Total noncurrent liabilities: 011
Total liabilities: 423
Stockholders' equity
Stockholders' equity attributable to parent, including: 14710
Preferred stock   0
Common stock 000
Additional paid in capital 806356
Accumulated other comprehensive income   0
Accumulated deficit (66)(57)(47)
Other undisclosed stockholders' equity attributable to parent 000
Stockholders' equity attributable to noncontrolling interest  (1)(1)
Total stockholders' equity: 1469
TOTAL LIABILITIES AND EQUITY: 18812

Income statement (P&L) ($ in millions)

9/30/2015
TTM
12/31/2014
12/31/2013
12/31/2012
Revenues 200
Revenue, net   0
Cost of revenue
(Cost of Goods and Services Sold)
 (1)(0)(0)
Gross profit: 100
Operating expenses (11)(11)(10)
Other undisclosed operating income 1  
Operating loss: (9)(10)(10)
Nonoperating income 001
Other nonoperating income 00 
Interest and debt expense  (0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes   0
Loss from continuing operations before equity method investments, income taxes: (9)(10)(9)
Other undisclosed income from continuing operations before income taxes  0 
Loss from continuing operations before income taxes: (9)(10)(9)
Income tax expense (benefit)  (0)1
Net loss: (9)(10)(8)
Net income attributable to noncontrolling interest 000
Net loss available to common stockholders, diluted: (9)(10)(7)

Comprehensive Income ($ in millions)

9/30/2015
TTM
12/31/2014
12/31/2013
12/31/2012
Net loss: (9)(10)(8)
Other comprehensive income   0
Other undisclosed comprehensive income   8
Comprehensive income (loss): (9)(10)0
Comprehensive income (loss), net of tax, attributable to noncontrolling interest 00(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  10(8)
Comprehensive loss, net of tax, attributable to parent: (9)(0)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: